NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at implementing two additional patient registries on its established NORD® IAMRARE® platform. This significant development is made possible through critical funding provided by the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®), a collaborative agreement with the Critical Path Institute that is funded by the U.S. Food and Drug Administration (FDA).
The initiative marks another milestone in the ongoing effort to empower rare disease communities by providing them with the necessary tools, infrastructure, and standardized platforms to collect robust patient-reported data. By expanding the IAMRARE platform, NORD continues to address the unique data collection challenges faced by rare disease advocacy organizations, helping them bridge the gap between patient experiences and actionable clinical research.
This collaborative funding opportunity reinforces the value of community-led research in the broader landscape of medical innovation. Stakeholders across the rare disease ecosystem have long recognized that comprehensive natural history data is essential for understanding disease progression, designing effective clinical trials, and ultimately bringing life-changing therapies to patients who have historically lacked treatment options.
Driving Research and Regulatory Progress Through Patient-Reported Data
The expansion of the IAMRARE platform directly supports NORD’s overarching mission to foster impactful research driven by rare disease nonprofits and patient advocacy groups. Research studies initiated and led by these communities have proven to be an invaluable source of real-world data, offering deep insights that traditional clinical settings often fail to capture.
"This opportunity builds on NORD’s work supporting rare disease nonprofits," says Tracey Sikora, Vice President of Research and Clinical Programs at NORD. "Research studies led by rare disease communities are an important source of data, and insights from IAMRARE-hosted studies have contributed to the development of clinical outcome assessments, updates to treatment guidelines, and at least one FDA approval."
The proven track record of the IAMRARE platform highlights the tangible impact that patient-centric data registries can have on regulatory pathways and medical guidelines. As regulatory agencies increasingly emphasize the importance of patient-reported outcomes, platforms that standardize and secure this information become vital assets for researchers, clinicians, and regulatory bodies alike.
Collaboration, Training, and Registry Development
Under this new application cycle, successful applicants will begin working closely with NORD starting in April 2027 to conceptualize, build, and officially launch a dedicated patient registry tailored to their specific rare disease community. NORD’s comprehensive support model is designed to guide advocacy organizations through every phase of the registry lifecycle, ensuring high standards of data integrity, security, and usability.
As part of this partnership, NORD will handle the technical development by building and hosting the registry website. Furthermore, NORD will provide extensive training and ongoing guidance to registry sponsors as they navigate a series of critical developmental steps. This includes establishing a dedicated registry advisory board, crafting a rigorous study protocol, building and customizing patient surveys, navigating the complex Institutional Review Board (IRB) process, and determining clear, ethical criteria for sharing the collected data with qualified researchers.
By offering this structured framework, NORD alleviates many of the administrative and technical burdens that typically hinder smaller patient advocacy organizations from launching successful data collection initiatives. This collaborative approach ensures that registries are built on a solid foundation capable of meeting rigorous scientific and regulatory standards.
Application Process, Timeline, and Criteria
The request for applications is currently open to eligible rare disease organizations seeking to establish a centralized platform for their patient communities. Interested organizations must carefully review the application guidelines and ensure they meet all necessary criteria before submitting their proposals.
The application window will remain open for several weeks, with the official submission deadline set for January 10, 2027. Following the close of the application period, NORD will review the submissions and notify accepted applicants by February 1, 2027. Preparations and implementation for the newly selected registries are scheduled to officially commence in April 2027.
Organizations interested in applying can access the submission portal online. Any questions or inquiries regarding the request for applications, eligibility, or the implementation process should be directed to NORD’s dedicated support team via email.
About the NORD® IAMRARE® Platform
The NORD® IAMRARE® Platform serves as a centralized, standardized, and secure online environment designed specifically to meet the needs of rare disease patient advocacy organizations. Currently, the platform hosts more than 55 live registries sponsored by various patient organizations with the primary purpose of collecting, managing, and utilizing patient-reported data. By standardizing data collection across diverse conditions, the platform facilitates cross-disease learning and enhances the visibility of rare conditions within the broader medical research community. Additional information regarding the platform and its capabilities can be found by visiting the official IAMRARE website.
About the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®)
The Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®) is an innovative, FDA-sponsored initiative created to provide a centralized and standardized infrastructure. Its core mission is to support and accelerate the characterization of rare diseases, with the ultimate goal of expediting the development of safe and effective therapies. By integrating diverse data types and providing a secure analytic workspace, RDCA-DAP empowers researchers to draw meaningful conclusions from sparse data. Further details about the initiative are available through the Critical Path Institute.
About the National Organization for Rare Disorders (NORD®)
Founded in 1983, the National Organization for Rare Disorders (NORD®) stands as a pioneering, independent, and nonpartisan nonprofit organization. NORD is steadfastly dedicated to improving the health, well-being, and lives of the more than 30 million Americans who are affected by rare diseases.
NORD operates through an extensive collaborative network, partnering with more than 350 disease-specific member patient organizations. Additionally, NORD collaborates closely with 49 designated NORD Rare Disease Centers of Excellence, which collectively span over 170 academic medical centers, premier research institutions, and children’s hospitals located nationwide. Through these powerful alliances, NORD advances comprehensive care, innovative research, targeted education, and robust public advocacy, working tirelessly to create a brighter and more equitable future for all individuals and families navigating the challenges of rare diseases.
For more information about NORD, its ongoing initiatives, and its programs, visit the organization’s official website.
Media Contact:
Cheryl Herbert
Vice President, Marketing & Communications
National Organization for Rare Disorders (NORD)
Email: [email protected]
